These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9201802)
21. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333 [TBL] [Abstract][Full Text] [Related]
22. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673 [TBL] [Abstract][Full Text] [Related]
23. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125 [TBL] [Abstract][Full Text] [Related]
24. Saturation of striatal D(2) dopamine receptors by clozapine. Nyberg S; Chou YH; Halldin C Int J Neuropsychopharmacol; 2002 Mar; 5(1):11-6. PubMed ID: 12057028 [TBL] [Abstract][Full Text] [Related]
25. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Seeman P; Van Tol HH Eur J Pharmacol; 1995 Oct; 291(2):59-66. PubMed ID: 8566176 [TBL] [Abstract][Full Text] [Related]
26. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Kapur S; Zipursky R; Remington G; Jones C; McKay G; Houle S Am J Psychiatry; 1997 Nov; 154(11):1525-9. PubMed ID: 9356559 [TBL] [Abstract][Full Text] [Related]
27. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376 [TBL] [Abstract][Full Text] [Related]
28. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Naiker DV; Catts SV; Catts VS; Bedi KS; Bryan-Lluka LJ Eur J Pharmacol; 2006 Jul; 540(1-3):87-90. PubMed ID: 16730699 [TBL] [Abstract][Full Text] [Related]
29. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Kapur S; Zipursky R; Jones C; Remington G; Houle S Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409 [TBL] [Abstract][Full Text] [Related]
30. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779 [TBL] [Abstract][Full Text] [Related]
31. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Schotte A; Janssen PF; Megens AA; Leysen JE Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574 [TBL] [Abstract][Full Text] [Related]
32. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Farde L; Wiesel FA; Halldin C; Sedvall G Arch Gen Psychiatry; 1988 Jan; 45(1):71-6. PubMed ID: 2892477 [TBL] [Abstract][Full Text] [Related]
33. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Turrone P; Remington G; Kapur S; Nobrega JN Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967 [TBL] [Abstract][Full Text] [Related]
34. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride. Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171 [TBL] [Abstract][Full Text] [Related]
35. Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Fitzgerald PB; Kapur S; Caligiuri MP; Jones C; Silvestri S; Remington G; Zipursky RB Neuropsychopharmacology; 2000 Jan; 22(1):19-26. PubMed ID: 10633487 [TBL] [Abstract][Full Text] [Related]
37. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Kapur S; Wadenberg ML; Remington G Can J Psychiatry; 2000 Apr; 45(3):241-6. PubMed ID: 10779880 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161 [TBL] [Abstract][Full Text] [Related]
40. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]